{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:39:01Z","timestamp":1794512341870,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013280","name":"Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["22KJA350003"],"award-info":[{"award-number":["22KJA350003"]}],"id":[{"id":"10.13039\/501100013280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021376","name":"Key Laboratory of Shaanxi Province for Complex System Control and Intelligent Information Processing","doi-asserted-by":"publisher","award":["NZYSKL240209"],"award-info":[{"award-number":["NZYSKL240209"]}],"id":[{"id":"10.13039\/501100021376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173664"],"award-info":[{"award-number":["82173664"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20785"],"award-info":[{"award-number":["U24A20785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX24_2301"],"award-info":[{"award-number":["KYCX24_2301"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020770","name":"Jiangsu Provincial Medical Youth Talent","doi-asserted-by":"publisher","award":["SLJ0321"],"award-info":[{"award-number":["SLJ0321"]}],"id":[{"id":"10.13039\/501100020770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20220109"],"award-info":[{"award-number":["BK20220109"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117783","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T02:44:32Z","timestamp":1747881872000},"page":"117783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Discovery of novel non-sulfonylurea NLRP3 inflammasome inhibitors for the treatment of multiple inflammatory diseases"],"prefix":"10.1016","volume":"295","author":[{"given":"Qi","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-325X","authenticated-orcid":false,"given":"Junwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117783_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ejmech.2025.117783_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.molmed.2022.02.010","article-title":"Role of inflammasomes in HIV-1 infection and treatment","volume":"28","author":"Jin","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117783_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.117783_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.117783_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2025.117783_bib6","first-page":"21","article-title":"NLRP3 inflammasome in neurodegenerative disease, translational research","volume":"252","author":"Anderson","year":"2023","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.117783_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105885","article-title":"NLRP3 inflammasome and IL-1\u03b2 pathway in type 2 diabetes and atherosclerosis: friend or foe?","volume":"173","author":"Chen","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.117783_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi9284","article-title":"NU6300 covalently reacts with cysteine-191 of gasdermin D to block its cleavage and palmitoylation","volume":"10","author":"Jiang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.117783_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 inflammasome in cancer and metabolic diseases","volume":"22","author":"Sharma","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2025.117783_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114890","article-title":"Recent advances in gout drugs","volume":"245","author":"Shi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117783_bib11","first-page":"197","article-title":"NAFLD: a critical role for the NLRP3 inflammasome in NASH, nature reviews","volume":"14","author":"Thomas","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.117783_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","article-title":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets","volume":"23","author":"Vande Walle","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117783_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117783_bib14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrd.2018.149","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117783_bib15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfv152","article-title":"Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays","volume":"147","author":"Shah","year":"2015","journal-title":"Toxicol. Sci. : Offic. J. Soc. Toxicol."},{"key":"10.1016\/j.ejmech.2025.117783_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology (Baltim., Md.)"},{"key":"10.1016\/j.ejmech.2025.117783_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115750","article-title":"Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: a recent update from 2019 to mid-2023","volume":"260","author":"Duan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117783_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/cpdd.1162","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral NLRP3 inflammasome inhibitor ZYIL1: first-In-human phase 1 studies (single ascending dose and multiple ascending dose)","volume":"12","author":"Parmar","year":"2023","journal-title":"Clinic. Pharmacol. Drug Develop."},{"key":"10.1016\/j.ejmech.2025.117783_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acs.jmedchem.0c01307","article-title":"Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space","volume":"64","author":"Schwaid","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117783_bib20","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1021\/acs.jmedchem.2c01250","article-title":"Overcoming preclinical safety obstacles to discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): a potent and selective NLRP3 inhibitor","volume":"65","author":"McBride","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117783_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1471","article-title":"A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis","volume":"13","author":"Klughammer","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.117783_bib22","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1021\/acs.jmedchem.4c02759","article-title":"Discovery of DFV890, a potent Sulfonimidamide-Containing NLRP3 inflammasome inhibitor","volume":"68","author":"Shen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117783_bib23","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1021\/acsptsci.4c00061","volume":"7","author":"Doedens","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.117783_bib24","doi-asserted-by":"crossref","first-page":"14897","DOI":"10.1021\/acs.jmedchem.3c01398","article-title":"Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders","volume":"66","author":"Harrison","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117783_bib25","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/cts.13576","article-title":"First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers","volume":"16","author":"Tang","year":"2023","journal-title":"Clinic. Translat. Sci."},{"key":"10.1016\/j.ejmech.2025.117783_bib26","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1021\/acs.jmedchem.3c01370","article-title":"Recent progress and prospects of small molecules for NLRP3 inflammasome inhibition","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117783_bib27","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.cell.2012.02.010","article-title":"Diabetes mellitus and the \u03b2 cell: the last ten years","volume":"148","author":"Ashcroft","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117783_bib28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cmdc.201700270","article-title":"Sulfonylureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors","volume":"12","author":"Hill","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117783_bib29","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1021\/acs.jmedchem.3c00175","article-title":"Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer","volume":"66","author":"Albanese","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117783_bib30","series-title":"Chemical Compounds, WO 2018167468 A1","author":"Harrison","year":"2018"},{"key":"10.1016\/j.ejmech.2025.117783_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127560","article-title":"Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors","volume":"30","author":"Harrison","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117783_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116455","article-title":"The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1","volume":"227","author":"Doedens","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117783_bib33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1124\/jpet.123.001941","article-title":"Target cell activation of a structurally novel NOD-like receptor pyrin domain-containing protein 3 inhibitor NT-0796 enhances potency","volume":"388","author":"Smolak","year":"2024","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.117783_bib34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cmet.2020.07.016","article-title":"The immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome activation","volume":"32","author":"Hooftman","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2025.117783_bib35","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202637","article-title":"ASC deglutathionylation is a checkpoint for NLRP3 inflammasome activation","volume":"218","author":"Li","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.117783_bib36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117783_bib37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00018-023-04881-x","article-title":"Discovery of a selective NLRP3-targeting compound with therapeutic activity in MSU-Induced peritonitis and DSS-Induced acute intestinal inflammation","volume":"80","author":"Zhou","year":"2023","journal-title":"Cell. Mol. Life Sci. : CMLS"},{"key":"10.1016\/j.ejmech.2025.117783_bib38","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1081\/SCC-120021029","article-title":"Novel synthesis of 1-(1,2,3,5,6,7-Hexahydro- s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea, an anti-inflammatory agent","volume":"33","author":"Urban","year":"2003","journal-title":"Synth. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:08:18Z","timestamp":1762265298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"alternative-id":["S0223523425005483"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117783","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel non-sulfonylurea NLRP3 inflammasome inhibitors for the treatment of multiple inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117783"}}